Highlights
- The company’s US subsidiary initiated voluntary recall of Buspirone Hydrochloride tablets.
- The recall was triggered by out-of-specification assay results during stability testing.
- No adverse events related to the recalled product have been reported so far.
Unichem Laboratories Limited (NSE:UNICHEMLAB) disclosed that its wholly owned subsidiary, Unichem Pharmaceuticals (USA), Inc., has voluntarily recalled Buspirone Hydrochloride Tablets, USP, in the United States. The affected product is the 5 mg strength supplied in 500-count bottles. The recall was initiated after identifying an out-of-specification (OOS) assay result at the 12-month long-term stability time point. The company clarified that no adverse events related to this issue have been reported to date.
Regulatory Context and Quality Measures
The recall has been undertaken voluntarily, reflecting a quality-related action identified during routine stability monitoring. The company stated that ensuring patient safety and maintaining product quality remains a priority across its manufacturing and supply chain processes. Such recalls are part of standard regulatory and compliance mechanisms in pharmaceutical markets, particularly in the United States.
Stock Performance Snapshot
Shares of Unichem Laboratories Limited were trading at ₹341.95, up ₹6.25 or 1.86% on April 13, 2026. The stock has recorded a gain of 13.87% over one week and 6.00% over one month. However, on a year-to-date basis, it has declined by 22.27%, while the one-year return stands at -40.10%. Over a three-year period, the stock has declined by 7.46%, reflecting broader price movement trends.
Key Risks
- Product quality issues leading to recalls impacting regulatory compliance.
- Potential financial impact from product withdrawal in the U.S. market.
- Reputation risk in key international pharmaceutical markets.
- Continued volatility in stock performance amid negative long-term returns.
Summary
Unichem Laboratories Limited disclosed a voluntary recall of Buspirone Hydrochloride tablets in the U.S. due to out-of-specification assay results. The company confirmed no adverse events linked to the recall. While the stock gained in the latest session, longer-term performance remains under pressure, with risks related to regulatory compliance, product quality, and market perception continuing to influence outlook.
FAQs
- Why did Unichem recall its product in the United States?
The recall was initiated due to an out-of-specification assay result identified during long-term stability testing of the product. - Which product has been recalled by Unichem?
Buspirone Hydrochloride Tablets, USP, 5 mg strength in 500-count bottles were recalled by its U.S. subsidiary. - Were there any adverse events reported due to the recall?
The company stated that no adverse events related to the recalled product have been reported so far.